Objective: The patients with ultra-short bowel syndrome (U-SBS) have been considered potential candidates for a preemptive/rehabilitative intestinal transplantation owing to the high risk of death from the underlying disease. We hypothesized that children with U-SBS, in the absence of intestinal failure-associated liver disease (IFALD), could also have a good rate of survival on home parenteral nutrition (HPN).
Methods: A prospective database from the “Bambino Gesù” Artificial Nutrition and Intestinal Failure Program was used to evaluate outcomes and morbidities of consecutive patients with ≤10 cm of small bowel enrolled since 2000.
Results: Eleven patients were identified with a median bowel length of 7.5 (3–9) cm. Eight patients developed IFALD, which reversed in 7 of them; the IFALD progressively worsened in 1 patient until death. One patient underwent isolated intestinal transplantation and 1 patient is no longer receiving parenteral nutrition (PN) and both are fully enterally fed. The other patients remained at least partially dependent on HPN. The number of days of inpatient care decreased in all of the patients except for the 1 who had repeated episodes of central line infections.
Conclusions: The survival of patients with U-SBS receiving HPN was good. Although IFALD was frequent, it had been manageable in most of the patients, but in a single complex case, it led to death. The multidisciplinary management warranted to these patients to approach the school age, to grow, and to maintain the oral intake. Patients with U-SBS are rare, and to better understand their long-term survival, further studies, including more large patient populations, are required.
*Hepatology, Gastroenterology and Nutrition Unit
†Department of Medical and Surgical Neonatology
‡Department of Paediatric Surgery and Transplantation, Bambino Gesù Children's Hospital, Rome, Italy.
Address correspondence and reprint requests to Antonella Diamanti, MD, Hepatology, Gastroenterology and Nutrition Unit, Bambino Gesù Children Hospital, Piazza S. Onofrio 4, 00165 Rome, Italy (e-mail: email@example.com).
Received 6 November, 2013
Accepted 6 November, 2013
The authors report no conflicts of interest.